共 334 条
[1]
Siegel RL(2023)Cancer statistics, 2023 CA Cancer J Clin 73 17-48
[2]
Miller KD(2019)Overall mortality after diagnosis of breast cancer in men vs women JAMA Oncol 5 1589-1596
[3]
Wagle NS(2017)Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients Clin Breast Cancer 17 356-366
[4]
Jemal A(2019)Breast cancer statistics, 2019 CA Cancer J Clin 69 438-451
[5]
Wang F(2021)Tumor subtypes and survival in male breast cancer Breast Cancer Res Treat 188 695-702
[6]
Shu X(2018)Breast cancer in men N Engl J Med 378 2311-2320
[7]
Meszoely I(2020)CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis Lancet Oncol 21 250-260
[8]
Pal T(2018)Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 J Clin Oncol 36 2465-2472
[9]
Mayer IA(2020)FDA approval summary: palbociclib for male patients with metastatic breast cancer Clin Cancer Res 26 1208-1212
[10]
Yu Z(2022)Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial Breast Cancer Res Treat 193 95-103